Vera Therapeutics shares are trading higher HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $10 to $25.
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co has maintained a Buy rating on Vera Therapeutics and raised its price target from $10 to $25, leading to a rise in the company's shares.
September 26, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics' stock price is likely to increase in the short term due to the raised price target and maintained Buy rating by HC Wainwright & Co.
Analyst ratings and price targets significantly influence stock prices. A maintained Buy rating indicates positive performance, while a raised price target suggests higher future value. Both these factors are likely to boost investor confidence and drive up VERA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100